Studies support the functional role of PBK in conferring tumor aggressiveness in GBM, showing that the treatment of glioma cells with PBK inhibitors reduces tumor volume in vivo (Joel et al., 2015; Sugimori et al., 2018) (Figure 3). This evidence concerns the gene PBK and glioblastoma.